ArticleFrontiers in medicine2026
Blood acylcarnitine profile alterations and fatty acid metabolism dysregulation associated with severe retinopathy of prematurity in preterm infants.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Retinopathy of prematurity (ROP) may be associated with abnormal retinal and systemic metabolic states. This study investigated the relationship between changes in free carnitine and acylcarnitine levels during the first postnatal week and the risk of severe ROP, and further explored their potential value for early risk assessment of severe ROP. Methods: In this retrospective cohort study, eligible infants underwent ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) testing within the first 7 days after birth. Free carnitine and acylcarnitine levels were compared between the ROP and the control group. Results: A total of 101 preterm infants were included in the ROP group, and 105 preterm infants were included in the control group. Except for 3-hydroxyisovalerylcarnitine (C5OH/C4DC), the levels of acetylcarnitine (C2), propionylcarnitine, glutarylcarnitine (C5DC/C6OH), adipylcarnitine, octenylcarnitine (C8:1), dodecanoylcarnitine, tetradecanoylcarnitine (C14), 3-hydroxytetradecanoylcarnitine, tetradecenoylcarnitine (C14:1), palmitoylcarnitine (C16), 3-hydroxypalmitoylcarnitine (C16OH), hexadecenoylcarnitine (C16:1), 3-hydroxyhexadecenoylcarnitine (C16:1OH), octadecanoylcarnitine (C18), 3-hydroxyoctadecanoylcarnitine, and 3-hydroxyoctadecenoylcarnitine (C18:1OH) were significantly lower in the severe ROP group than in the control group (all Conclusion: Infants in the ROP group exhibited alterations in the acylcarnitine profile, which may reflect changes in fatty acid metabolism, and these alterations might be associated with severe ROP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.